Comparative Pharmacology
Head-to-head clinical analysis: LONSURF versus TECVAYLI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LONSURF versus TECVAYLI.
LONSURF vs TECVAYLI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LONSURF (trifluridine and tipiracil) is a combination of the thymidine-based nucleoside analogue trifluridine and the thymidine phosphorylase inhibitor tipiracil. Trifluridine incorporates into DNA and inhibits cell proliferation, while tipiracil increases trifluridine exposure by inhibiting its degradation by thymidine phosphorylase.
Bispecific T-cell engager antibody that binds to BCMA on multiple myeloma cells and CD3 on T-cells, leading to T-cell activation and targeted cytotoxicity.
Adults: 35 mg/m2 orally twice daily on days 1-5 and 8-12 of each 28-day cycle.
Subcutaneous injection: Step-up dosing schedule. First dose 0.06 mg/kg, then 0.3 mg/kg on day 4, followed by 1.5 mg/kg weekly starting day 7. Maximum single dose 1.5 mg/kg.
None Documented
None Documented
Trifluridine: terminal half-life approximately 1.4-2.1 hours; tipiracil: terminal half-life approximately 2-3 hours. Clinical context: short half-lives necessitate twice-daily dosing on Days 1-5 and 8-12 of a 28-day cycle.
22.5 days (range 10–35 days) based on population pharmacokinetic analysis; supports every-2-week dosing after step-up.
Primarily renal: tipiracil is excreted unchanged in urine (approximately 50% of dose); trifluridine is eliminated via metabolism and renal excretion (as metabolites and unchanged drug). Fecal elimination accounts for <3% of total clearance.
Primarily catabolized to small peptides and amino acids; not expected to be excreted renally or hepatically to a significant extent.
Category C
Category C
Antineoplastic
Antineoplastic